A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
An Almost Normal Life Expectancy for People With HIV?
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Misleading News Reports Suggest HIV Cure Is Near
New HIV Drug Class Shows Promise
Gene Therapy Shows Promise in Controlling HIV
Potential Microbicide Tricks HIV Into Sudden Death
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

September 4, 2012

Norvir-Boosted Reyataz Linked to High Kidney Stone Risk

People living with HIV using Norvir (ritonavir)-boosted Reyataz (atazanavir) were roughly ten times more likely to experience kidney stones, compared with those using other Norvir-boosted protease inhibitor (PI)-based regimens, according to a review of patient data conducted by Japanese researchers published online ahead of print by Clinical Infectious Diseases. In their analysis of 1,240 people treated with a Norvir-boosted PI regimen between 2004 and 2010, 35 HIV-positive individuals experienced kidney stones—31 (88.5 percent) of whom were using Norvir-boosted Reyataz. The kidney stone incidence rate was 7 percent among those using Norvir-boosted Reyataz, compared with 0.5 percent among those using other Norvir-boosted PI regimens.  Additionally, six of 18 people who continued using Norvir-boosted Reyataz after being diagnosed with kidney stones experienced a recurrence after an average of five months. Norvir-boosted Reyataz “should be carefully prescribed to patients with predisposing factors for renal stone formation or those with chronic kidney disease,” the authors conclude. “For those who developed [Norvir-boosted Reyataz]-induced renal stones, discontinuation of [the regimen] is warranted because of the high risk of recurrence.”

To read the Clinical Infectious Diseases article (paid subscription required), click here.

Search: hiv, kidney stones, neprhrolithiasis, renal stones, atazanavir, reytaz, norvir, ritonavir, japan, tokyo


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (2 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    chrisf
    san jose
    California


    usuallyhappy
    Palm Springs
    California


    Fred9774
    Brooklyn
    New York


    thebake
    Sioux Falls
    South Dakota
Click here to join POZ Personals!
Conference Coverage

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


20th Conference on Retroviruses and Opportunistic Infections
(CROI 2013)
Atlanta, GA
March 3 - 7, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.